The regenerative medicine industry has a communication problem, and it isn’t a scientific one. The field now broadly accepts that mesenchymal stem/stromal cells (MSCs) exert their effects largely through paracrine signaling rather than engraftment and differentiation, a reframing captured in Arnold Caplan’s proposal to rename them “medicinal signaling cells.” What hasn’t matured is the public’s understanding of any of it. [Read more…]
Aspen Neuroscience Receives FDA RMAT for Sasineprocel (ANPD001), an Autologous iPSC-Based Therapy for PD
SAN DIEGO, July 30, 2026 — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson’s Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). [Read more…]